Johnson & Johnson (JNJ)vsOrganiGram Holdings Inc (OGI)
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
OGI
OrganiGram Holdings Inc
$0.83
-0.65%
HEALTHCARE · Cap: $117.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 32029% more annual revenue ($99.33B vs $309.18M). OGI leads profitability with a 28.0% profit margin vs 16.2%. OGI trades at a lower P/E of 1.9x. OGI earns a higher WallStSmart Score of 58/100 (C).
JNJ
Buy54
out of 100
Grade: C-
OGI
Buy58
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 49.4% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bull Case : OGI
The strongest argument for OGI centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 28.0% and operating margin at -2.2%. Revenue growth of 49.4% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Bear Case : OGI
The primary concerns for OGI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while OGI is a growth play — different risk/reward profiles.
OGI carries more volatility with a beta of 1.98 — expect wider price swings.
OGI is growing revenue faster at 49.4% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
OGI scores higher overall (58/100 vs 54/100), backed by strong 28.0% margins and 49.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →OrganiGram Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?